Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-04-2023 | SARS-CoV-2 | Case report

Remdesivir

Fever and bradycardia: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Scotto R, et al. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines 11: 200, No. 2, Feb 2023. Available from: URL: http://www.mdpi.com/journal/vaccines Scotto R, et al. Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines 11: 200, No. 2, Feb 2023. Available from: URL: http://​www.​mdpi.​com/​journal/​vaccines
Metadata
Title
Remdesivir
Fever and bradycardia: 2 case reports
Publication date
01-04-2023
Publisher
Springer International Publishing
Keyword
SARS-CoV-2
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-37786-9

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Ciclosporin

Case report

Cefazolin

Case report

Yttrium 90